Form 4: Lyell CEO Sells Shares for Tax Obligations
Insider Transaction Report
Lyell Immunopharma's President and CEO, Lynn Seely, sold shares of common stock to cover tax withholding obligations related to vested restricted stock units.
Summary
- Lynn Seely, President and CEO of Lyell Immunopharma, Inc. (LYEL), reported sales of common stock.
- On August 11, 2025, 391 shares were sold at a weighted average price of $10.526 per share, with prices ranging from $10.045 to $11.00.
- On August 12, 2025, 406 shares were sold at a weighted average price of $10.338 per share, with prices ranging from $10.120 to $10.415.
- These sales were non-discretionary, executed automatically to cover tax withholding obligations from the settlement of vested restricted stock units.
- Following these transactions, Lynn Seely beneficially owns 34,828 shares of Lyell Immunopharma common stock.
- All share amounts and prices reported reflect a 1-for-20 reverse stock split effected by the Issuer on May 30, 2025.
Sentiment
Score: 5
Explanation: The filing reports routine, non-discretionary sales of shares by an insider to cover tax obligations, which is a neutral event and does not indicate a change in sentiment towards the company.
Future Outlook
No forward-looking statements or guidance are provided in this filing, as it is a report of insider transactions.
Industry Context
This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes, not indicative of a change in management's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/30/2025 | Issuer effected a 1-for-20 reverse stock split of its common stock. |
| 08/11/2025 | Sale of 391 shares of common stock by Lynn Seely to cover tax withholding obligations. |
| 08/12/2025 | Sale of 406 shares of common stock by Lynn Seely to cover tax withholding obligations. |
| 08/13/2025 | Signature date of the Form 4 filing. |
Recommendation
holdThe filing details routine, non-discretionary sales by an insider to cover tax obligations on vested equity. This type of transaction is common and does not reflect a change in the insider's view of the company's prospects or fundamental value, thus not warranting a change in investment recommendation based solely on this filing.
Keywords
Lyell Immunopharma, LYEL, Form 4, Insider Transaction, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.